-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HSW4hncmjsxGdR7DAYNgn6wM1CoJ+dt1J/Zytjm9qelDARGI72a2mIBVj97qHb9V Yk5jiy/4OCWiTQa3JNHdyg== 0001362310-06-000371.txt : 20061122 0001362310-06-000371.hdr.sgml : 20061122 20061122130025 ACCESSION NUMBER: 0001362310-06-000371 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20061121 ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant FILED AS OF DATE: 20061122 DATE AS OF CHANGE: 20061122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-33393 FILM NUMBER: 061235442 BUSINESS ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: 4256083008 MAIL ADDRESS: STREET 1: 18701 120TH AVENUE NE STREET 2: SUITE 100 CITY: BOTHELL STATE: WA ZIP: 98011 8-K 1 c70095e8vk.htm FORM 8-K Form 8-K
 

 
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) November 21, 2006
 
NORTHWEST BIOTHERAPEUTICS, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
 
         
DELAWARE
(STATE OR OTHER
JURISDICTION
OF INCORPORATION) 		 
0-33393
(COMMISSION FILE
NUMBER) 		 
94-3306718
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
18701 120th Avenue NE, Suite 101, Bothell, WA 98011
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
 
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE (425) 608-3000
 
INAPPLICABLE
(FORMER NAME OR FORMER ADDRESS IF CHANGED SINCE LAST REPORT)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

 

 

ITEM 2.03 Creation of a Direct Financial Obligation.
On November 21, 2006, Northwest Biotherapeutics, Inc. (the “Company”) received a cash advance in the amount of $500,000 from Toucan Partners, LLC (“Toucan”). The Company and Toucan are presently negotiating the terms pursuant to which this cash advance will be required to be repaid.

 

 

 

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
November 22, 2006  NORTHWEST BIOTHERAPEUTICS, INC.
 		  
  By:   /s/ Alton Boynton    
    Alton L. Boynton   
    President   
 

 

 

-----END PRIVACY-ENHANCED MESSAGE-----